SUMM.L Regulatory News (SUMM)

29 Aug 2007 14:05

Summit Corporation PLC29 August 2007 Summit Corporation plc("Summit" or "the Company") DIRECTOR SHAREHOLDINGS Executives purchase shares Oxford, UK, 29 August 2007 - Summit Corporation plc (AIM: SUMM) announces that atotal of 44,630 Ordinary Shares of 10 pence per share were purchased today bythree of the Company's Executive Directors. The Ordinary Shares were purchasedat a price of 122 pence. The details of the transactions are set out below: +-----------------+----------+-------+-------------------+-----------------+|Executive |Number of | Price |Aggregate number of| % of Ordinary ||Director | shares | (p) | Ordinary Shares | Shares in issue || |purchased | |beneficially owned | beneficially || | | | following the | owned following || | | | purchase | the purchase |+-----------------+----------+-------+-------------------+-----------------+|Steven Lee | 24,344 | 122 | 182,492 | 0.37% |+-----------------+----------+-------+-------------------+-----------------+|Richard Storer | 16,229 | 122 | 16,229 | 0.03% |+-----------------+----------+-------+-------------------+-----------------+|Darren Millington| 4,057 | 122 | 5,168 | 0.01% |+-----------------+----------+-------+-------------------+-----------------+ - ENDS - For more information, please contact:+---------------------------------------------------+-------------------------+|Summit plc | ||Steven Lee, PhD, Chief Executive Officer | ||Darren Millington, ACMA, Chief Financial Officer |Tel: +44 (0)1235 443951 ||Richard Pye, PhD, Investor Relations | || | |+---------------------------------------------------+-------------------------+|Citigate Dewe Rogerson | ||Mark Swallow / David Dible / Valerie Auffray |Tel: +44 (0)207 638 9571 || | |+---------------------------------------------------+-------------------------+|Evolution Securities | ||Tim Worlledge / Bobbie Hilliam / Neil Elliot |Tel: +44 (0)207 071 4300 || | |+---------------------------------------------------+-------------------------+ About Summit plc Summit plc is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced carbohydrate chemistry and drug screening (chemicalgenomics) technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. Summit plc has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. Summit plc's in-house drug development capabilities combine world-classexpertise in both carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: SUMM Further information about the company is available at www.summitplc.com This document contains "forward-looking statements" within the meaning of theU.S. Private Securities Litigation Reform Act of 1995. Forward-lookingstatements can be identified by words such as "anticipates", "intends", "plans","seeks", "believes", "estimates", "expects" and similar references to futureperiods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations andassumptions regarding our business, the economy and other future conditions.Because forward-looking statements relate to the future, by their nature, theyare subject to inherent uncertainties, risks and changes in circumstances thatare difficult to predict. The Company's actual results may differ materiallyfrom those contemplated by the forward-looking statements. The Company cautionsyou therefore that you should not rely on any of these forward-lookingstatements as statements of historical fact or as guarantees or assurances offuture performance. Important factors that could cause actual results to differmaterially from those in the forward-looking statements and regional, national,global political, economic, business, competitive, market and regulatoryconditions. This information is provided by RNS The company news service from the London Stock Exchange